产品名称
3A-MPLA, Avanti Research™ - A Croda Brand 699851P, powder
assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699851P-1mg), pkg of 1 × 5 mg (699851P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 699851P
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
InChI
1S/C54H103N2O17P.H3N/c1-4-7-10-13-16-19-20-23-26-29-32-35-46(61)70-41(34-31-28-25-22-18-15-12-9-6-3)37-45(60)56-48-51(64)52(73-74(66,67)68)42(38-57)72-54(48)69-39-43-49(62)50(63)47(53(65)71-43)55-44(59)36-40(58)33-30-27-24-21-17-14-11-8-5-2;/h40-43,47-54,
InChI key
WBMOMCHVNLUEBA-MWYCKLIASA-N
General description
Monophosphoryl lipid A (MPLA) is an analog of the lipid A moiety. It is regarded as a detoxified derivative of the lipopolysaccharide (LPS).
Biochem/physiol Actions
Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. It induces tumor necrosis factor and interleukin (IL)-1β, however not as efficient as lipopolysaccharide (LPS). MPLA improves immune response during bacterial sepsis infection.
Packaging
2 mL Amber Glass Crimp Cap Vial (699851P-1mg)
2 mL Amber Glass Crimp Cap Vial (699851P-5mg)
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
No data available
flash_point_c
No data available